Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term

FOR IMMEDIATE RELEASE:
December 18, 2013
Contact: 

Gaye Walker
571-483-1357
gaye.walker@asco.org

Julie M. Vose, MD, MBA, FASCO, an internationally recognized expert in the treatment of lymphoma, has been elected President of the American Society of Clinical Oncology (ASCO) for a one-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the ASCO Board of Directors and two new members to the ASCO Nominating Committee.

“ASCO is a very diverse and multifaceted organization with so much to offer its membership. The recent enhancements in the educational offerings, quality improvement, broadened advocacy, and the potential for comparative effectiveness research with CancerLinQ™ are just a few of the ASCO areas where I believe my experience and training will add to the current activities,” Dr. Vose said. “I am excited to serve the ASCO membership as President and to make a difference for oncology professionals and our patients.”

Dr. Vose is the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology Division in the Department of Internal Medicine at the University of Nebraska Medical Center, and the Associate Director of Clinical Research and Co-Chair of the Lymphoma Program at the Fred and Pamela Buffet Cancer Center. Since joining ASCO in 1991, she has served on the Board of Directors, as Chair of the Cancer Education Committee, and is the current Chair-Elect of the Integrated Media and Technology Committee, among other activities.

Since 2006, Dr. Vose has served as the Associate Director of Clinical Research and is Co-Chair of the Lymphoma Program at the Fred and Pamela Buffet Cancer Center. She is a member of the Board of Directors for the University of Nebraska Medical Center Physicians Group. She is Co-Chair of the Lymphoma Steering Committee for the National Cancer Institute and serves on the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee.

Newly Elected ASCO Board Members
ASCO’s Board of Directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field. The following physicians will begin four-year terms as members of ASCO’s Board of Directors starting in June 2014:

Linda D. Bosserman, MD, FACP, has been elected to a Community Oncologist seat. She is President of the Wilshire Oncology Medical Group, Inc., in Los Angeles, California. Since joining ASCO in 1990, Dr. Bosserman has served on the Quality Care Symposium Planning Committee and Practice Guidelines Implementation Network, among other activities. She was a member of the White House Physician Forum on Health Reform in 2009. She has led her practice’s work on oncology medical home care.

David Khayat, MD, PhD, FASCO, has been elected to an International Oncologist seat. He is the Head of the Department of Medical Oncology at Pitié-Salpêtrière Hospital, in Paris, France. Since joining ASCO in 1987, he has served as Chair of the International Affairs Committee, on the Cancer Education Committee, and as Associate Editor of the Journal of Clinical Oncology, among other activities. He has served as President of the French National Cancer Institute and the French Federation of Medical Oncologists.

Walter J. Curran, Jr., MD, FACR, has been elected to a Radiation Oncologist seat. He is the Executive Director of the Winship Cancer Institute of Emory University and the Lawrence W. Davis Professor and Chairman of Emory’s Department of Radiation Oncology. Since joining ASCO in 1988, Dr. Curran has served on the Cancer Research Committee, the Cancer.Net Editorial Board, and the Conquer Cancer Foundation Advanced Clinical Research Award (ACRA) in Glioma Subcommittee, among other activities. He is one of three founding principal investigators of the new NCI-funded cooperative group NRG Oncology and the Founding Chair of the NRG Oncology Foundation Board.

Charles D. Blanke, MD, FACP, FRCPC, FASCO, has been elected to an Undesignated Specialty seat. He is a Professor of Medicine at the Oregon Health & Science University Knight Cancer Institute in the Division of Hematology and Medical Oncology. Since joining ASCO in 1995, Dr. Blanke has served as Chair of the Cancer Education Committee, Co-Chair of the Gastrointestinal Cancers Symposium Program Committee, and on the Journal of Clinical Oncology Editorial Board, among other activities. He is the current Chair of the Southwest Oncology Group (SWOG).

Newly Elected Members of ASCO Nominating Committee
Two newly elected ASCO Nominating Committee members will serve three-year terms beginning in June 2014:

Gregory H. Reaman, MD, FASCO, is the Associate Director of the U.S. Food and Drug Administration’s Office of Hematology and Oncology Products, a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences, and an Adjunct Professor of Oncology and Pediatrics at Georgetown University School of Medicine. Since joining ASCO in 1978, he has served on the Board of Directors, the Cancer Survivorship Committee, and as Chair of the Membership Committee, among other activities. He is a past Chair of the Children’s Oncology Group.

David R. Spriggs, MD, is Head of the Division of Solid Tumor Oncology and the Winthrop Rockefeller Chair of Medical Oncology at Memorial Sloan-Kettering Cancer Center and a Professor of Medicine at Weill Cornell Medical College. Since joining ASCO in 1986, he has served on the Scientific Program Committee, Chair of the Grants Selection Committee, and as an Associate Editor of the Journal of Clinical Oncology, among other activities. He currently serves as an Associate Editor of the New England Journal of Medicine. Dr. Spriggs will serve as the 2016-2017 Chair of the Nominating Committee.

About ASCO

The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.